FIELD: medicine.
SUBSTANCE: invention refers to medicine and consists in a liposome containing a bilayer membrane and inner aqueous phase. The inner aqueous phase contains sulphobutyl ester cyclodextrin salt formed by sulphobutyl ester cyclodextrin with one or more of ammonium hydroxide, triethylamine and triethanolamine and an active substance specified in vinorelbine, vincristine, topotecan and irinotecan. The invention also refers to a method for producing the above liposome and a liposomal pharmaceutical agent containing the above liposome.
EFFECT: controlling the active substance release from the liposome.
8 cl, 10 ex, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| LIPOSOMAL COMPOSITIONS USED FOR DRUG DELIVERY | 2015 |
|
RU2757110C2 |
| LIPOSOMAL COMPOSITIONS APPLICABLE FOR DRUG DELIVERY | 2005 |
|
RU2574926C2 |
| STABILIZED PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN | 2016 |
|
RU2732567C2 |
| LIPOSOMAL PHARMACEUTICAL PREPARATION AND METHOD FOR PREPARING IT | 2007 |
|
RU2494729C2 |
| LIPOSOMAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2734900C1 |
| PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF WEAK ACID DRUGS AND ITS USE | 2019 |
|
RU2810790C2 |
| LIPOSOMAL COMPOSITION | 2010 |
|
RU2476216C1 |
| CREATING CONTROLLED RELEASE PROFILE OF DRUG SUBSTANCE USING LIPOSOMAL COMPOSITION IN AQUEOUS AND ANHYDROUS SOLUTIONS | 2014 |
|
RU2712157C2 |
| READY-TO-USE FORMULATION FOR LIPOSOMAL INJECTION OF VINCRISTINE SULFATE | 2016 |
|
RU2676762C1 |
| STABLE LIPOSOMAL COMPOSITIONS | 2004 |
|
RU2369384C2 |
